Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.58 |
| ▸ | ITGA2 | P17301 | 3/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349307 | 1.00 | ITGB3 (0.58) | ITGB3ITGA2ALOX5LMNACYP26A1 | |
| SCHEMBL350064 | 0.95 | ITGB3 (0.62) | ITGB3ITGA2ALOX5LMNACYP26A1 | |
| SCHEMBL350063 | 0.95 | ITGB3 (0.62) | ITGB3ITGA2ALOX5LMNACYP26A1 | |
| SCHEMBL3679858 | 0.86 | CA2 (0.48) | ITGB3ITGA2ALOX5SMN1; SMN2PKM | |
| SCHEMBL3681590 | 0.86 | ITGB3 (0.47) | ITGB3ITGA2ALOX5LMNACYP26A1 | |
| SCHEMBL4462369 | 0.86 | ITGB3 (0.47) | ITGB3ITGA2ALOX5LMNACYP26A1 | |
| SCHEMBL2850903 | 0.84 | NPC1 (0.57) | ITGB3ITGA2CYP26A1KMT2AMEN1 | |
| SCHEMBL4028148 | 0.81 | NPC1 (0.54) | ITGB3ITGA2KMT2AMEN1MAPT | |
| SCHEMBL7591232 | 0.81 | NPC1 (0.54) | ITGB3ITGA2KMT2AMEN1MAPT | |
| SCHEMBL4028151 | 0.81 | NPC1 (0.54) | ITGB3ITGA2KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8647882-B2 | Chiral selectors and stationary phases for separating enantiomer mixtures | EVONIK DEGUSSA GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8268631-B2 | Chiral selectors and stationary phases for separating enantiomer mixtures | EVONIK DEGUSSA GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20120015443-A1 | NOVEL CHIRAL SELECTORS AND STATIONARY PHASES FOR SEPARATING ENANTIOMER MIXTURES | EVONIK DEGUSSA GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20090229352-A1 | NOVEL CHIRAL SELECTORS AND STATIONARY PHASES FOR SEPARATING ENANTIOMER MIXTURES | EVONIK DEGUSSA GMBH (DE) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015443-A1 | NOVEL CHIRAL SELECTORS AND STATIONARY PHASES FOR SEPARATING ENANTIOMER MIXTURES | BCAT2, BCAT1, SLC43A1 | ITGB3 3802/4885ITGA2 3095/4885ALOX5 4649/4885 |
| US-20090229352-A1 | NOVEL CHIRAL SELECTORS AND STATIONARY PHASES FOR SEPARATING ENANTIOMER MIXTURES | BCAT2, BCAT1, SLC43A1 | ITGB3 3802/4885ITGA2 3095/4885ALOX5 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.